SEC Comment Letter 0000000000-23-013886 to Amylyx Pharmaceuticals, Inc. (AMLX)

Amylyx Pharmaceuticals, Inc.
Date: Dec. 20, 2023 · CIK: 0001658551 · Accession: 0000000000-23-013886

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 001-41199

Date

December 20, 2023

Author

Not clearly detected

Form

UPLOAD

Company

Amylyx Pharmaceuticals, Inc.

Letter

United States securities and exchange commission logo December 20, 2023 James Frates Chief Financial Officer Amylyx Pharmaceuticals, Inc. 43 Thorndike St. Cambridge, MA 02141 Re:Amylyx Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2022 Filed March 13, 2023 File Number 001-41199 Dear James Frates: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

United States securities and exchange commission logo
December 20, 2023
James Frates
Chief Financial Officer
Amylyx Pharmaceuticals, Inc.
43 Thorndike St.
Cambridge, MA 02141
Re:Amylyx Pharmaceuticals, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2022
Filed March 13, 2023
File Number 001-41199
Dear James Frates:
            We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io